News Medical on MSN
Gene therapy shows long-term success in children with rare immune disorder
Results from the largest cohort of children who received a gene therapy for a rare immunodeficiency condition have shown the ...
After axing a wide swath of federal research projects and grants, a recent slew of awards offers a glimpse into the kinds of ...
University College London's National Amyloidosis Center leads a multinational team reporting that a single infusion of an in ...
CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...
Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class ...
Company is Developing EN-374 as a One-Time Treatment for X-Linked Chronic Granulomatous Disease Ensoma, a genomic medicines company advancing the future of medicine through one-time, in vivo therapies ...
DURHAM, N.C.--(BUSINESS WIRE)-- Precision BioSciences, Inc. (DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, ...
The illustration shows how high trafficking of blood stem cells in the circulation early post-natally allows lentiviral-vector mediated in vivo gene transfer. “After birth, blood stem cells need to ...
Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse ...
Gene-editing techniques — and particularly base editing, which allows precise editing of single nucleotides — have the potential to correct many disease-causing genetic variants. However, efforts to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback